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Abstract
To become infectious, HIV-1 particles undergo a maturation process involving proteolytic cleavage of the Gag and Gag-Pol
polyproteins. Immature particles contain a highly stable spherical Gag lattice and are impaired for fusion with target cells.
The fusion impairment is relieved by truncation of the gp41 cytoplasmic tail (CT), indicating that an interaction between the
immature viral core and gp41 within the particle represses HIV-1 fusion by an unknown mechanism. We hypothesized that
the conformation of Env on the viral surface is regulated allosterically by interactions with the HIV-1 core during particle
maturation. To test this, we quantified the binding of a panel of monoclonal antibodies to mature and immature HIV-1
particles by immunofluorescence imaging. Surprisingly, immature particles exhibited markedly enhanced binding of several
gp41-specific antibodies, including two that recognize the membrane proximal external region (MPER) and neutralize
diverse HIV-1 strains. Several of the differences in epitope exposure on mature and immature particles were abolished by
truncation of the gp41 CT, thus linking the immature HIV-1 fusion defect with altered Env conformation. Our results suggest
that perturbation of fusion-dependent Env conformational changes contributes to the impaired fusion of immature
particles. Masking of neutralization-sensitive epitopes during particle maturation may contribute to HIV-1 immune evasion
and has practical implications for vaccine strategies targeting the gp41 MPER.
Citation: Joyner AS, Willis JR, Crowe JE Jr, Aiken C (2011) Maturation-Induced Cloaking of Neutralization Epitopes on HIV-1 Particles. PLoS Pathog 7(9): e1002234.
doi:10.1371/journal.ppat.1002234
Editor: Alexandra Trkola, University of Zurich, Switzerland
Received January 15, 2011; Accepted July 8, 2011; Published September 8, 2011
Copyright:  2011 Joyner et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by grants from the National Institutes of Health (R01 AI47056 and T32 HL069765). Image acquisition and analysis was performed
in part through the use of the VUMC Cell Imaging Shared Resource (supported by NIH grants CA68485, DK20593, DK58404, HD15052, DK59637, and EY08126).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: chris.aiken@vanderbilt.edu
Introduction
HIV-1 fusion is mediated by the Env glycoprotein, a trimeric
complex of heterodimers composed of the surface glycoprotein (SU)
gp120 and the transmembrane glycoprotein (TM) gp41. Fusion of
virions with targetcells takes place through a series of eventsinitiated
by binding of gp120 to CD4 on the surface of the target cell
(reviewed in [1]). CD4 binding induces conformational changes in
gp120thatpermitexposureofthecoreceptor-bindingsite,composed
of the bridging sheet (consisting of four discontinuous anti-parallel
beta strands) and the third hypervariable (V3) loop. Subsequent
engagement of CD4-bound gp120 by a chemokine coreceptor—
either CCR5 or CXCR4—triggers dramatic conformational
changesingp41 that resultinfusion of viral and cellularmembranes.
A common feature of lentiviruses is that their TM proteins have
long cytoplasmic tails. HIV-1 gp41 encodes a 152 amino acid
cytoplasmic tail (CT), while TM proteins of simple retroviruses
have tails of 20–50 amino acids in length [2]. Several activities
have been attributed to the gp41 CT, including polarized budding
of HIV-1 particles from epithelial cell monolayers [3], rapid
internalization of Env from the cell surface [4,5], incorporation of
Env into virions during particle assembly [6,7], and interaction
with Pr55
Gag during virion assembly [5,6,7,8,9].
To become infectious, newly formed HIV-1 particles must
undergo a process of maturation involving specific cleavage of the
major structural polyprotein Pr55
Gag by the viral protease.
Immature HIV-1 particles contain stable cores and are non-
infectious due to defects in early post-entry steps of the life cycle
[10]. However, recent studies have demonstrated that immature
virions are also impaired for fusion with target cells and that the
gp41 CT plays a key role in repressing immature HIV-1 particle
fusion [11,12,13].
The detailed mechanism by which HIV-1 fusion is regulated by
structural changes within the core has not been determined, but
one recent study attributed the repression to a change in physico-
mechanical properties (i.e. ‘‘stiffness’’) that accompanies HIV-1
maturation [14]. An alternative hypothesis is that maturation
triggers a conformational change in the ectodomain of the Env
glycoprotein complex, releasing it into a fusion-competent state.
Such a mechanism might also limit the exposure of neutralization-
sensitive epitopes in gp120 and gp41, thus promoting immune
evasion. Previous work has revealed that the gp41 CT modulates
Env conformation on HIV-1, HIV-2, and SIV, thus lending
support to the latter hypothesis [15,16,17].
To test whether HIV-1 particle maturation alters the confor-
mation of the Env proteins, we used a sensitive and quantitative
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of full-length and CT-truncated Env proteins on mature and
immature HIV-1 particles. The results revealed specific epitopes in
gp120 and gp41 that exhibit greater exposure on immature vs.
mature virions, including two in the membrane-proximal external
region (MPER). Therefore, Env trimers on immature virions are
present in an exposed conformation, and neutralization-sensitive
epitopes undergo conformational masking during particle matu-
ration.
Results
Immunofluorescence-based detection of gp120 and
gp41 epitopes on HIV-1 particles
To analyze Env conformation on HIV-1 particles, we developed
a sensitive and quantitative imaging-based assay for binding of
antibodies to virions. The assay was designed to permit the use of a
panel of available conformation-specific monoclonal antibodies
(mAbs) specific for gp120 and gp41. HIV-1 particles, containing a
GFP-Vpr fusion protein, were immobilized on glass cover slips and
stained using an indirect immunofluorescence protocol. To avoid
potential artifacts resulting from fixation, Env-specific primary
antibodies were bound under native conditions. After washing to
remove unbound antibodies, antibody-bound virions were fixed
with paraformaldehyde and detected by addition of a fluorescent,
Cy5-conjugated secondary antibody. By this approach, the gp120-
specific mAb 2G12 readily detected wild-type HIV-1 particles, as
seen by the colocalization between the GFP-labeled virions and
the Cy5 antibody fluorescence (Fig. 1, top row). As a control, Env-
defective HIV-1 particles were not bound by 2G12, thus
establishing the specificity of the assay (Fig. 1, bottom row).
The imaging-based assay detects antibody binding to individual
HIV-1 particles, allowing for analysis of the distribution in staining
intensities among a population of virions. The binding signal
generally exhibited a broad distribution, with the bulk of the
particles exhibiting low-level binding with a wide tail toward
higher binding. Wild-type HIV-1 particles have been reported to
contain approximately 10 Env trimers, with considerable variabil-
ity among virions [18]. In the example shown for mAb 4E10
binding, a larger percentage of mature, wild type virions exhibited
a lower average intensity than immature virions while more
immature virions had high average intensities (Fig. S1A). The
change in median average intensity per particle observed over the
distribution was also apparent in the fluorescence images (Fig. S2).
These are examples of data used to quantitatively compare the
binding of antibodies to mature and immature HIV-1 particles.
Representative histograms for each antibody are included in the
supporting information.
As an additional control, the fluorescence distribution for Env-
defective immature particles was determined for mAb 4E10 and
mAb b12 binding. As expected, there was no difference between
the binding to mature and immature particles lacking HIV-1 Env
(Fig. S3), and the binding to each was minimal.
To facilitate interpretation of the particle imaging data,
immunoblotting of viral lysates was performed to compare Env
levels on virions (Fig. S4A). Quantification of band intensities
revealed a difference of no more than 20% between mature and
immature particles (Fig. S4B). Consistent with our previous work
and that of others [8,13], we observed higher TM/SU ratios on
both mature and immature particles lacking the gp41 CT, owing
to the elevated TM protein association with HIV-1 particles. Since
our analyses focused mainly on pairwise comparisons between
mature and immature particles, the elevated gp41 levels on CT-
truncated particles does not represent a confounding factor. We
conclude that the quantitative differences in immunodetection of
Env on the surface of mature and immature HIV-1 particles result
from differences in Env conformation.
Env trimers are present in an altered conformation on
immature HIV-1 particles
As an initial test to compare conformations of Env proteins on
mature and immature virions, we tested the binding of HIV-Ig, a
polyclonal IgG pool isolated from HIV-1 infected individuals.
Under the optimized experimental conditions, Env-defective HIV-
1 particles were not bound by HIV-Ig, indicating that staining was
specific for Env (Fig. 2). We observed that the median staining
intensity was 28% higher for immature versus mature particles.
Immature HIV-1 particles lacking the gp41 cytoplasmic tail also
exhibited elevated staining with HIV-Ig relative to the corre-
sponding CT-truncated mature particles; however, this increase
was not statistically significant. Because the imaging-based assay
permits quantification of antibody binding to each particle, we also
examined the distribution of HIV-Ig antibody binding (Fig. S5).
Analysis of the distribution revealed that the bulk of the particles
bound lower quantities of antibodies, with a tail toward higher
binding levels. These results indicate that while some of the HIV-1
Env epitopes recognized by HIV-Ig exhibit enhanced exposure on
immature particles, the gp41 CT is not required for the enhanced
antibody binding. However, some antigenic elements on the
surface of HIV-1 virions could be masked by cleavage of the Gag
Figure 1. Quantitative imaging-based assay to detect Env
conformations. HIV-1 virions containing a GFP-Vpr fusion protein
were plated on glass cover slips, incubated with an Env-specific mAb,
fixed, incubated with a Cy5-conjugated secondary antibody, and
mounted. Samples were imaged using a Zeiss LSM 510 META inverted
confocal microscope. Top row: wild-type HIV-1 particles; bottom row:
Env negative HIV-1 particles.
doi:10.1371/journal.ppat.1002234.g001
Author Summary
The conformation of HIV-1 Env is of tremendous impor-
tance from an immunological standpoint. While several
human monoclonal antibodies that exhibit broadly neu-
tralizing activity have been identified, efforts to elicit such
antibodies have met with minimal success. Here, we show
that the conformation of Env is altered on the surface of
immature vs. mature HIV-1 particles in such a way that
certain epitopes recognized by some broadly neutralizing
antibodies are more exposed on immature virions. This
maturation-dependent conformational masking may rep-
resent an important mechanism of HIV-1 immune evasion.
HIV-1 Maturation Controls Env Conformation
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specific Env epitopes differ between immature and mature virions
and whether such differences depend on the gp41 CT.
Conformation-independent antibodies directed toward
gp120 are not altered during HIV-1 maturation
MAb 2G12 specifically recognizes N-linked glycans in the C2,
C3, C4, and V4 domains of gp120 [19]; binding of this antibody is
thus independent of gp120 conformation. Accordingly, we
observed no significant difference in mAb 2G12 binding to
mature and immature virions (Fig. 3A, Fig. S6A). However, mAb
2G12 binding was increased by 35% on immature virions
containing a truncated gp41 CT, consistent with a previous report
that truncation of the CT enhances mAb 2G12 binding to Env
expressed on the cell surface [15].
MAb B4e8 recognizes the V3 loop in gp120. We observed that
mAb B4e8 binding to immature particles was increased by 15%
relative to mature HIV-1 virions (Fig. 3B, Fig. S6B). On CT-
truncated particles, the 15% increase in binding to immature
particles was retained. However, neither of these differences was
statistically significant, suggesting that exposure of the mAb B4e8
epitope is not markedly altered during HIV-1 maturation. The
data from these two conformation-independent antibodies also
corroborates the conclusion from the immunoblot analysis that the
levels of gp120 are not significantly different on mature vs.
immature virions.
Immature HIV-1 virions are not impaired for CD4 binding
A previous study reported that mature and immature HIV-1
particles are equally competent for binding to CD4+ T cells [13].
To test whether HIV-1 maturation alters the conformation of the
CD4 binding site on gp120, we quantified the binding of mAb
b12, which recognizes an epitope overlapping the CD4 binding
site. MAb b12 bound mature and immature virions to an
equivalent extent, suggesting that the region of gp120 recognized
by this antibody is not structurally altered on the surface of
immature HIV-1 particles (Fig. 4A, Fig. S7A). Curiously, the CT-
deleted Env bound significantly more mAb b12 when present on
immature vs. mature particles. Overall, these data suggest that the
epitope recognized by mAb b12 is exposed to a similar extent on
mature and immature HIV-1 particles and that the gp41 CT
appears to modulate exposure of this epitope differentially on
mature vs. immature particles.
To quantify CD4 binding to HIV-1 particles, we utilized CD4-
IgG2, a fusion protein in which four copies of the V1 and V2
domains of human CD4 replace the heavy and light chain Fv
portions of human IgG2. Because sCD4 has been shown to induce
gp120 shedding to a different extent on mature vs. immature virions
[20], we asked whether differential shedding contributed to the
results obtained for CD4-IgG binding. For this purpose, we
incubated HIV-1 particles with soluble CD4 (sCD4) and stained
with mAb 2G12, whose binding should be unaffected by the
conformational state of gp120. We found that while the mAb 2G12
signal decreased by 22% for mature HIV-1, the signal for immature
HIV-1 decreased by only 11% (Fig. S8). Likewise, the mature CT-
truncated virus signal decreased by 20%, and the immature tail-
truncated virus signal decreased by only 3%. When the binding
results were normalized by the observed levels of gp120 shedding,
we observed no difference in binding of sCD4-IgG2 to mature and
immature virions (Fig. 4B, Fig. S7B). Collectively, these results
suggest that the CD4 binding site on gp120 is not structurally
altered on the surface of immature virions. The data further
demonstrate that the fusion impairment associated with immature
viruses is not owing to a quantitative defect in CD4 binding.
Immature HIV-1 virions are competent for CD4-induced
gp120 conformational changes
CD4 binding induces structural rearrangements in gp120,
exposing epitopes recognized by the mAbs E51, A1g8, and 17b,
Figure 2. Binding of polyclonal human antibodies to HIV-1
virions. HIV-1 virions containing GFP-Vpr were treated as described in
the legend to Figure 1. The intensity of Cy5 antibody staining to HIV-1
particles was analyzed with Metamorph. The data were compiled from
four independent experiments where six independent fields containing
on average 200–600 particles were evaluated for the median average
intensity. N=4; standard errors of the mean are shown. The data were
analyzed using Wilcoxon rank-sum tests. WT: wild type HIV-1; PR:
protease defective HIV-1; DCT: gp41 cytoplasmic tail-truncated HIV-1.
doi:10.1371/journal.ppat.1002234.g002
Figure 3. Analysis of exposure of the gp120 V3 loop and gp120
glycans on the surface of mature and immature HIV-1 particles.
N=3 (2G12 binding to DCT and PR-DCT), 4 (2G12 binding to WT and
PR-, B4e8); error bars represent SEM. (A) mAb 2G12 binding; (B) mAb
B4e8 binding.
doi:10.1371/journal.ppat.1002234.g003
Figure 4. Binding of IgG1 b12 and CD4-IgG2 to HIV-1 particles.
HIV-1 virions were processed and analyzed as described in the legend
to Figure 2. N=3 (b12 binding to DCT and PR-DCT), 4 (b12 binding to
WT and PR-, CD4-IgG2); error bars represent SEM. (A) IgG1 b12 binding;
(B) CD4-IgG2 binding.
doi:10.1371/journal.ppat.1002234.g004
HIV-1 Maturation Controls Env Conformation
PLoS Pathogens | www.plospathogens.org 3 September 2011 | Volume 7 | Issue 9 | e1002234which overlap the coreceptor-binding site in gp120 [21,22]. We
employed these antibodies in combination with soluble CD4
(sCD4), and taking into account the levels of sCD4-induced gp120
shedding, to quantify CD4-induced conformational changes on
the surface of mature or immature HIV-1 particles. In the absence
of sCD4, mAbs E51 and A1g8 binding to gp120 was approxi-
mately 20% greater on immature vs. mature HIV-1 particles
(Fig. 5A and B, black bars, Fig. S9E and H). By contrast, binding
of mAb 17b to immature particles was approximately 40% less
than binding to mature particles (Fig. 5C, Fig. S9B). We also tested
the effects of sCD4 on the binding of these antibodies (Fig. 5A–C,
white bars, Fig. S9C,F,I). Binding of each antibody to immature
virions was stimulated by sCD4 to a greater or equal extent vs.
mature particles, with mAb 17b exhibiting the greatest increase
(Fig. 5D). Truncation of the CT abolished the enhanced sCD4-
induced binding of mAbs A1g8 and 17b to immature particles.
Collectively, these results demonstrate that CD4 binding triggers
exposure of some epitopes to an equal extent on immature and
mature virions and other epitopes to a greater extent on immature
virions. Furthermore, the involvement of the gp41 CT links the
enhanced epitope exposure to the fusion impairment associated
with immature HIV-1 particles.
Immature HIV-1 particles exhibit enhanced exposure of
specific epitopes in gp41
The fusion protein gp41 contains several epitopes that are
exposed preferentially when Env is in a fusion-active conforma-
tion. MAb 50–69 binds at the C-terminal end of the N-terminal
heptad repeat region of gp41 [23]. Binding of mAb 50–69 to
immature particles was approximately 75% greater than to mature
particles, a difference that was highly significant (Fig. 6A, Fig.
S10A and B). Increased binding also was observed on particles
lacking the gp41 CT. Thus, the Env protein on the surface of
immature virions exhibits greater exposure of the mAb 50–69
epitope, but this conformational difference does not depend on the
CT.
MAb 5F3 is a gp41-specific antibody that recognizes an epitope
adjacent to the fusion peptide. We observed that mAb 5F3 binding
to immature virions was approximately twice that of mature
virions (Fig. 6B, Fig. S10C and D). When the CT was truncated,
mAb 5F3 binding to mature particles was increased, but binding to
mature and immature particles was equivalent. Thus, virion
maturation masks the epitope recognized by mAb 5F3, and
truncation of the gp41 CT abolishes this effect.
The accessibility of the gp41 MPER is altered on
immature HIV-1 particles
The MPER of gp41 is the target of several broadly neutralizing
antibodies (bnAbs). The antigenic epitopes in this region of gp41
may be hidden from immune recognition, since the presence of
such bnAbs is rare in infected patients. We tested the MPER-
specific mAbs 2F5, Z13e1, and 4E10 for binding to mature and
immature HIV-1 particles. Binding of mAbs 4E10 and Z13e1 to
immature particles was greater than to mature virions (70% and
100% increase, respectively), and in both cases the increase was
abolished by truncation of the gp41 CT (Fig. 7A and B, Fig. S1A–
D). For mAb 2F5, slightly greater binding to immature particles
was apparent, but the observed difference was not statistically
significant (Fig. 7C, Fig. S1E and F).
On average, the MPER-specific mAbs 4E10 and Z13e1 bound
immature particles approximately 1.5 to 2 times as well as mature
particles when the median binding signals were compared.
Examination of the distributions revealed that the differences
resulted from increases in the percentage of immature particles at
higher antibody binding levels (Fig. S1A and C). Analysis of mAb
Z13e1-bound particles with an average intensity above 15 a.u.
revealed a greater than 2-fold increase in binding to immature
HIV-1 virions (Fig. S1D); analysis of mAb 4E10-bound particles
with an average intensity above 50 a.u. revealed a 6-fold increase
in binding to immature HIV-1 virions (Fig. S1B). We conclude
that MPER-specific mAbs exhibit enhanced binding to immature
HIV-1 particles, and the gp41 CT plays a role in controlling
accessibility of MPER epitopes.
To test whether the increased binding was an effect of avidity
caused by bivalent interaction with full-length IgG forms of the
mAbs rather than increased affinity of the antibody combining site
with the epitopes, we tested the binding to particles of Fab
fragment forms of mAbs that were directly labeled with
fluorophore. Consistent with the results using whole antibodies,
Figure 5. Analysis of sCD4-induced conformational changes on
HIV-1 virions. HIV-1 virions were processed and analyzed as described
in the legend to Figure 2. Filled bars: no sCD4. Open bars: with sCD4.
N=3(DCT and PR-DCT), 4 (A1g8 and E51 binding to WT and PR-), 5 (17b
binding to WT and PR-); error bars represent SEM. (A) mAb E51 binding;
(B) mAb A1g8 binding; (C) mAb 17b binding; (D) quantitation of sCD4-
induced antibody binding.
doi:10.1371/journal.ppat.1002234.g005
Figure 6. Antibody binding to non-neutralizing gp41 epitopes
on HIV-1 virions. N=3 (50–69 and 5F3 binding to DCT and PR-DCT), 4
(50–60 and 5F3 binding to WT and PR-); error bars represent SEM. (A)
mAb 50–69 binding; (B) mAb 5F3 binding.
doi:10.1371/journal.ppat.1002234.g006
HIV-1 Maturation Controls Env Conformation
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vs. mature HIV-1 particles (Fig. S11), and the effect was abolished
by truncation of the gp41 CT. By contrast, binding of Fab b12 did
not exhibit a statistically significant difference. We conclude that
MPER-specific antibodies exhibit preferential binding to imma-
ture HIV-1 particles and the gp41 CT contributes to the enhanced
binding. These results reinforce the conclusion that the epitope
recognized by mAb 4E10 is more accessible on immature HIV-1
particles.
Discussion
In this study, we observed quantitative differences in epitope
exposure on the surface of mature and immature HIV-1 particles
using a novel single particle imaging-based binding assay. Several
important epitopes exhibited increased exposure on the surface of
immature HIV-1 particles. Specifically, exposure of the gp41
epitopes recognized by mAbs 50–69 and 5F3, and the MPER-
specific mAbs Z13e1 and 4E10, were markedly increased on the
surface of immature particles. By contrast, binding of mAb 17b,
which recognizes a CD4-induced epitope, was lower for immature
vs. mature particles. However, the accessibility of the CD4-
induced epitope recognized by mAb 17b was generally increased
on immature vs. mature particles. Taken together, the results
indicate that the conformation of Env is altered on the surface of
immature vs. mature HIV-1 particles, suggesting that the
conformational of Env is altered during HIV-1 particle matura-
tion.
Understanding the conformations of Env is of tremendous
importance from an immunological perspective. HIV-1 rapidly
evolves to evade the host antibody response, yet a current view is
that an effective HIV-1 vaccine will require both humoral and
cellular virus-specific responses. Despite considerable effort,
attempts to elicit antibody responses that neutralize a wide range
of HIV-1 isolates have been unsuccessful. Nonetheless, several
human mAbs have been identified that exhibit broadly neutral-
izing activity, indicating that such antibodies can be produced in
vivo, although they are rare. An area of intense study is the MPER
region of gp41, which is the target of several bnAbs. In the current
study, we show that the epitopes recognized by mAbs Z13e1 and
4E10 are bound more readily when present on immature particles,
indicating that these epitopes become masked during HIV-1
particle maturation. Such conformational masking may represent
an important mechanism of HIV-1 immune evasion, and
immunization strategies targeting the MPER may benefit from
focused approaches utilizing structurally engineered antigens
informed by studies of immature HIV-1 particles. Therefore, a
detailed understanding of the conformation of Env on immature
particles could aid in the design of recombinant HIV-1
immunogens.
In the present study, we primarily analyzed the binding of full-
length IgG antibodies rather than monovalent Fabs. Because IgG
molecules are bivalent, their binding could be stabilized by avidity
effects, which in turn could depend on the proximity of Env
complexes on the virion surface. Our previous work showed that
the Env proteins form a stable complex with the core within
immature HIV-1 particles that depends on the gp41 CT. In
mature virions, or particles lacking the gp41 CT, the Env trimers
may be free to move laterally on the virion surface, thus allowing
for patching of Env trimers. Thus, differences in antibody binding
might be due, at least in part, to avidity effects resulting from
altered trimer mobility in the viral membrane. To address this, we
tested the binding of b12 and 4E10 Fab proteins, and the results
agreed with the binding of the corresponding full-length IgG
antibodies. Therefore, avidity effects seem unlikely to account for
the enhanced antibody binding observed for immature particles,
on which the patching of Env would be limited. Thus, our results
are more consistent with the interpretation that immature particles
exhibit increased exposure of specific epitopes vs. differential
antibody-induced patching of Env trimers.
Previous work by our group and another demonstrated that
immature HIV-1 particles are repressed for fusion with target cells
by an activity that requires the gp41 CT [11,13]. In the present
study, we sought to test whether the repressed fusion of immature
particles might be due to restricted conformational changes on the
surface of immature particles. The tight association of both Env
subunits with immature particles, observed even following
detergent treatment, suggested that the Env might be locked in
a ‘‘cloaked’’ fusion-inactive conformation owing to association of
the gp41 CT with the highly stable Gag polyprotein lattice [8].
This cloaking mechanism would have the benefit of protecting the
HIV-1 Env complex from neutralizing antibodies during the
maturation process. Our results were surprising: exposure of
several neutralization-sensitive Env epitopes was greater on
immature particles. Several of the maturation-dependent confor-
mational differences we observed were abolished by truncation of
the gp41 CT, indicating that the CT couples Env conformation to
particle maturation. CD4-induced binding of the gp120-specific
antibody 17b also was enhanced on immature particles, and
truncation of gp41 suppressed the enhanced binding. Therefore,
our results establish that the gp41 CT alters the conformation of
the Env ectodomains on immature particles, potentially interfering
with the receptor-dependent conformational changes required for
fusion. It is possible, however, that the enhanced sCD4-induced
Figure 7. Analysis of neutralizing gp41 MPER epitopes. N=3 (2F5 binding to DCT and PR-DCT, Z13e1), 4 (2F5 binding to WT and PR-, 4E10
binding to DCT and PR-DCT), 6 (4E10 binding to WT and PR-); error bars represent SEM. (A) mAb 4E10 binding; (B) mAb Z13e1 binding; (C) mAb 2F5
binding.
doi:10.1371/journal.ppat.1002234.g007
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with immature particles. Murakami et al. previously reported that
immature HIV-1 particles are not impaired for binding of a mAb
(NC-1) that recognizes the 6-helix bundle (6HB) conformation,
which is thought to form at a late stage of the fusion process [13].
Specifically, the authors observed that addition of sCD4 induced
equivalent binding of mAb NC-1 to mature and immature
particles. While this result could suggest that the Env trimers on
immature particles are competent for fusion-dependent confor-
mational changes, it is not clear that mAb NC-1 binding to cell-
free virions necessarily reflects a conformational change specific to
fusion. Indeed, a recent study has shown that NC-1 recognizes
other forms of gp41 besides the 6HB [24]. Therefore, it remains
plausible that the differential binding of selected mAbs to mature
and immature HIV-1 particles reflects conformational differences
that contribute to the fusion impairment exhibited by immature
HIV-1 virions.
Based on our results, we propose a model in which a strong
Gag-Env association constrains the Env subunits, particularly
gp41, into an exposed conformation, and that receptor engage-
ment is insufficient to drive the additional conformational changes
necessary for fusion. The model also implies that the MPER-
specific bnAbs act by trapping gp41 in a conformational
intermediate formed during particle maturation. Our results do
not exclude other potential effects contributing to impaired fusion,
such as altered physico-mechanical properties associated with
immature particles bearing full-length Env proteins [14]. It should
be noted that the present work employed a laboratory-adapted
HIV-1 clone, which is likely hypersensitive to CD4. Fusion of
viruses containing Env proteins from primary HIV-1 isolates is
also regulated by maturation [25], and it will be important to
extend the present studies to such Env proteins.
Materials and Methods
Cells and viruses
293T cells were cultured at 37uC and 5% CO2 in Dulbecco’s
Modified Eagle medium (DMEM; Cellgro) supplemented with
fetal bovine serum (10%), penicillin (50 IU/mL), and streptomycin
(50 mg/mL). The proviral DNA constructs used for the production
of HIV-1 have been described previously [11] and are as follows:
R9, wild-type HIV-1; R9.PR-, protease-defective HIV-1 contain-
ing a triple alanine substitution in the protease active site;
R9Tr712, HIV-1 containing a truncation of the gp41 C-terminal
144 amino acids; R9Tr712.PR-, protease-defective HIV-1 con-
taining a truncation of the gp41 C-terminal 144 amino acids.
Viruses were produced by transient transfection of 293T cells in
10 cm dishes with 20 mg of proviral DNA and 7 mg of a GFP-Vpr
fusion protein expression vector [26] using a calcium phosphate-
based method [27]. Virus stocks were harvested 48 h after
transfection and clarified through 0.45 mm syringe filters. Aliquots
were buffered with 10 mM HEPES pH 7.3 prior to storage at
280uC. HIV-1 stocks were assayed for p24 by enzyme-linked
immunosorbent assays (ELISAs) as previously described [8,28],
after boiling in SDS-PAGE loading buffer to solubilize the
hyperstable immature particles.
Antibodies and CD4 proteins
The following reagents were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: CD4-IgG2 from Progenics Pharmaceuticals; HIV-1
gp120 mAb 2G12 and HIV-1 gp41 mAbs 5F3, 2F5, and 4E10
from Dr. Hermann Katinger; HIV-1 gp120 mAbs F425 B4e8 and
F425 A1g8 from Dr. Marshall Posner and Dr. Lisa Cavacini;
HIV-1 gp120 mAb IgG1 b12 from Dr. Dennis Burton and Carlos
Barbas; HIV-Ig from NABI and NHLBI; HIV-1 gp120 mAbs 17b
and E51 from Dr. James E. Robinson; HIV-1 gp41 mAb 50–69
from Dr. Susan Zolla-Pazner; HIV-1 gp41 mAb IgG1 Z13e1 from
Dr. Michael Zwick; sCD4-183 from Pharmacia, Inc.
Production and labeling of purified recombinant Fabs
Amino acid sequences for Fabs b12 and 4E10 were obtained
from the Protein Data Bank (PDB IDs 2NY7 and 2FX7). DNAs
encoding the Fab protein sequences were designed and optimized
for mammalian cell expression systems and synthesized commer-
cially (GeneArt, Regensburg, Germany). The Fab DNAs were
cloned into the pEE6.4 heavy chain expression vector (Lonza
Group Ltd, Basel, Switzerland) with a recombinant stop codon
placed before the constant region, to specify Fabs. The light chain
cDNAs also were expressed in recombinant form using a
mammalian cell optimized sequence that had been cloned into
the pEE12.4 light chain vector (Lonza). The plasmids were
transformed into DH5 strain E. coli cells for EndoFree Plasmid
Maxi DNA preparation (Qiagen, Hilden, Germany). Transient
transfection of each heavy and light chain combination for
expression of Fab proteins in the serum-free HEK 293F cell
expression system (Invitrogen, Carlsbad, CA) was accomplished
using PolyFect reagent (Qiagen) according to the manufacturer’s
instructions. Supernatants were collected after 120 hours of
expression and Fabs were purified using FPLC with a KappaSelect
prepacked column (GE HealthCare Life Sciences, Piscataway, NJ)
in D-PBS and concentrated in 15 mL centrifugal filter units with
30 kDa molecular weight cut-off (Millipore, Billerica, MA). A high
level of purity of the Fabs was confirmed using a non-reducing
SDS-PAGE and a Coomassie Blue stain (Invitrogen) that did not
reveal contaminating proteins. The Fabs were shown to bind in
ELISA as expected to HIV-1 virus-like particles or to recombinant
gp120 molecules [29] to confirm their functionality before further
study. Purified 4E10 and b12 Fabs were directly labeled using the
Alexa Fluor 647 Microscale Protein Labeling Kit (Invitrogen)
according to the manufacturer’s instructions.
Antibody binding assay for HIV-1 particles
HIV-1 virions were plated on poly-D-lysine coated dishes
(MatTek). Virions were incubated with an Env-specific mAb
(except in the case of polyclonal HIV-Ig) for two hours at room
temperature, fixed in 2% paraformaldehyde for 15 min at room
temperature, washed five times with PBS, incubated with a Cy5-
conjugated anti-human IgG (Jackson ImmunoResearch Labora-
tories, Inc.) at a concentration of 14 mg/mL for one hour at room
temperature, washed five times with PBS, mounted, and imaged
using a Zeiss LSM 510 META inverted confocal microscope.
Image acquisition was performed using a 636objective lens with
26optical zoom with line averaging for a 102461024 pixel image.
GFP imaging was performed with an excitation wavelength of
488 nm and band pass 505–550 emission filter. Cy5 imaging was
performed with an excitation wavelength of 633 nm and a long
pass 650 emission filter. For preincubation with sCD4, viruses
were incubated in suspension with 0.25 mg/mL 2-domain sCD4-
183 for 30 min at room temperature prior to plating and addition
of primary antibody. To optimize the assay for detecting
differences in epitope exposure, each antibody was first titrated
on wild-type and Env-deficient virions. Antibody concentrations
giving minimal staining of Env-deficient virions and a non-
saturated level of staining with wild-type virions were employed
(Table S1). This allowed each antibody to be used within its
dynamic range, so that any differences in binding to the viruses
could be detected. Final antibody concentrations are provided in
HIV-1 Maturation Controls Env Conformation
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tions were selected as the optimal concentrations that exhibited
minimal background and were not saturating thus allowing
detection of quantitative changes in epitope exposure.
Labeled 4E10 and b12 Fabs (1 mg/mL) were used in virus
binding assays as described in the text. The only alteration to the
protocol was eliminating the secondary antibody incubation and
mounting immediately after the post-fixation washes.
Image and data analysis
MetaMorph software (Molecular Devices) was used to quantify
the average intensity of Cy5 staining for each GFP-positive
particle. Particles were defined as adjacent groups of green pixels,
or regions, above a background intensity of 20 graylevels in an
area with a width and height between 0.2 and 0.8 microns. These
regions were overlayed on the Cy5 image, and both the area and
average signal intensity were calculated for each region. As can be
seen in Figs. 1 and S2, not all Cy5 stained spots colocalize with a
GFP region. We hypothesize that these spots are either HIV-1
particles that did not incorporate sufficient GFP-Vpr to be
detected, or are microvesicles containing HIV-1 Env. Since Cy5
intensity was measured within regions defined by the presence of
GFP, these GFP-negative particles were excluded from analysis.
To verify that analyzing the average intensity for each particle
would not skew the data, size distributions were generated for each
virus type using the data from two independent mAb 4E10 and
mAb b12 staining experiments (Fig. S12). These distributions,
together with the absence of a correlation between the average
GFP intensity per particle and particle area (Fig. S13B), showed
that the apparent particle areas were not different for each type of
HIV-1 virus used. In addition, there is no correlation between the
average GFP intensity per particle and the average Cy5 (4E10)
intensity per particle (Fig. S13A) and also no correlation between
average Cy5 (4E10) intensity per particle and particle area (Fig.
S13C). Of note, the observed higher levels of 4E10 binding
occurred over the full range of particle sizes (Fig. S13C).
Data points are the median average intensity per particle of six
independent fields (each contained approximately 200–600
particles) obtained from at least three independent experiments.
These results were used in Wilcoxon rank-sum tests to evaluate
statistical significance of observed differences. As a reference point,
the particle size (Fig. S12) and the antibody binding histograms
(Fig. S1,5,6,8,9,10) indicate the number of particles from one
independent experiment (the combination of six images) used to
generate the plots.
Immunoblotting of viral lysates
Viruses particles were pelleted through a 20% sucrose cushion.
Pellets were resuspended in SDS-PAGE sample buffer. Virion
quantities were normalized based on p24 ELISA results prior to
electrophoresis on 4%–20% SDS-PAGE gels (Bio-Rad) and
transfer to nitrocellulose. Nitrocellulose was blocked in 5% nonfat
dry milk in PBS containing 0.1% Tween-20. Primary antibodies
were used as follows: gp120 mAb 2G12 (1 mg/mL), gp41 mAb 2F5
(1.25 mg/mL), CA 183-H12-5C (0.75 mg/mL). Secondary anti-
bodies were donkey anti-human IgG IRDye800 (Rockland) and
goat anti-mouse IgG DyLight680 (Thermo Scientific). Blots were
scanned using the LI-COR Odyssey Imaging System, and bands
were quantified using the instrument software.
Histogram representation of antibody binding data
To generate example histograms for each antibody, the intensity
values for each particle from six independent images acquired
from one experiment were binned into 1 arbitrary unit (a.u.) bins.
The percentage of particles falling within each bin was calculated
based on the total number of particles, as indicated in the legend
for each histogram, in the population. The y-axis scale was set to
maximally visualize the WT, PR-, DCT, and PR- DCT virus
populations. Therefore, the maximal value for the Env- population
is indicated in parentheses in the top left corner of each plot.
Cutoff analysis
To determine the percentage of particles stained above a cutoff
intensity, as indicated by the white arrow and dotted line on the
histograms, the average intensity values for each particle from six
independent images acquired from one experiment (with the
corresponding histogram representing one such experiment) were
combined and analyzed as a single unit. The percentage of
particles above the cutoff for each virus population in each
experiment was calculated. These values were averaged for each
virus and presented with the standard error of the mean. Each
data point includes values from between three and six independent
experiments.
Assay of sCD4-induced gp120 shedding
To assess the level of gp120 shedding from mature and
immature HIV-1, we quantified the level of mAb 2G12 binding
following incubation with sCD4 under the conditions used for
quantifying CD4-induced binding of mAb 17b. The HIV-1 viruses
were plated on poly-D-lysine coated MatTek dishes, incubated
with 0.25 mg/mL sCD4 for 30 min at room temperature,
incubated with 1 mg/mL mAb 2G12 for 2 hours at room
temperature, fixed in 2% paraformaldehyde for 15 min at room
temperature, washed five times with PBS, incubated with a Cy5-
conjugated anti-human IgG for one hour at room temperature,
washed five times with PBS, mounted, and imaged. Image
acquisition and data analysis were performed exactly as described
in the text.
Supporting Information
Figure S1 Distribution of antibody binding intensities
for mAbs 4E10, Z13e1, and 2F5. (A) mAb 4E10. (C) mAb
Z13e1. (E) mAb 2F5. The particles analyzed from six fields imaged
during one independent experiment were combined and binned
into 1 a.u. bins for distribution analysis. The numbers in
parentheses at the top left corner of the plots indicate the percent
particles per bin value at which the Env- samples peaked. The
numbers in the parentheses next to the virus types in the legend
represent the number of particles in each distribution. The arrows
and dashed line indicate the cutoff level used in panels B, D, and
F. The cutoff levels were selected by visual inspection of the
distributions with the intent to determine whether the antibody
binding differences are altered at high levels of binding. (B) mAb
4E10. (D) mAb Z13e1. (F) mAb 2F5. The percentages of particles
with intensity greater than 50 a.u. for 4E10, 15 a.u. for Z13e1, and
15 a.u. for 2F5 were calculated. This value represents the area
under the curve for each virus that falls above the cutoff intensity.
N=3 (2F5 binding to DCT and PR- DCT, Z13e1), 4 (2F5 binding
to WT and PR-, 4E10 binding to DCT and PR- DCT), 6 (4E10
binding to WT and PR-); error bars represent SEM.
(PDF)
Figure S2 Imaging of mAb 4E10 stained mature and
immature HIV-1 virions. The median average intensity per
particle of the PR- image is 1.4-fold higher than that of the wild-
type image.
(PDF)
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deficient immature virions. PR-Env- virions were stained
with (A and C) mAb b12 (1 mg/mL) or (B and D) mAb 4E10
(0.25 mg/mL). The staining distributions were plotted (A and B).
The numbers within the parentheses are the percent particles per
bin values at which the Env- and PR-Env distributions peaked.
The median average intensity per particle for each virus is shown
in C and D.
(PDF)
Figure S4 Immunoblotting of viral lysates to compare
Env levels. (A) Immunoblots of pelleted viral lysates with
detection of gp41 (1.25 mg/mL mAb 2F5), gp120 (1 mg/mL
mAb 2G12), and CA (0.75 mg/mL 183-H12-5C); (B) Quantifica-
tion of relative band intensities using LI-COR Odyssey Imaging
System software.
(PDF)
Figure S5 Distribution of antibody binding intensities
for HIV-Ig. The particles analyzed from six fields imaged during
one independent experiment were combined and binned into 1
a.u. bins for distribution analysis. The number in parentheses at
the top left corner of the plot indicates the percent particles per bin
value at which the Env- sample peaked. The values in the
parentheses next to the virus types in the legend represent the
number of particles in the corresponding distribution.
(PDF)
Figure S6 Distribution of antibody binding intensities
for mAbs 2G12 and B4e8. The particles analyzed from six
fields imaged in an individual experiment were combined and
binned into 1 a.u. bins for distribution analysis. The numbers in
parentheses at the top left corner of the plots indicate the percent
particles per bin value at which the Env- samples peaked. The
values in the parentheses next to the virus types in the legend
represent the number of particles in the corresponding distribu-
tion. (A) mAb 2G12. (B) mAb B4e8.
(PDF)
Figure S7 Distribution of antibody binding intensities
for mAb b12 and CD4-IgG2. The particles analyzed from six
fields imaged during one independent experiment were combined
and binned into 1 a.u. bins for distribution analysis. (A) mAb b12;
(B) CD4-IgG2.
(PDF)
Figure S8 Analysis of sCD4-induced gp120 shedding.
HIV-1 particles were incubated with sCD4 (0.25 mg/mL) for
30 min at room temperature before staining with 2G12 (1 mg/
mL). Samples were treated identically as the samples stained with
the CD4i antibodies with the exception of the primary antibody
used. The values represent the percentages of 2G12 staining on
the sCD4 treated sample relative to the untreated sample.
(PDF)
Figure S9 Distribution of antibody binding intensities
for mAbs 17b, E51, and A1g8. The particles analyzed from six
fields imaged during one independent experiment were combined
and binned into 1 a.u. bins for distribution analysis. (A) Overlay of
panels B and C. (B) mAb 17b without sCD4. (C) mAb 17b with
sCD4. (D) Overlay of panels E and F. (E) mAb E51 without sCD4.
(F) mAb E51 with sCD4. (G) Overlay of panels H and I. (H) mAb
A1g8 without sCD4. (I) mAb A1g8 with sCD4.
(PDF)
Figure S10 Distribution of antibody binding intensities
for mAbs 5F3 and 50–69. (A) mAb 5F3. (C) mAb 50–69. The
particles analyzed from six fields imaged during one independent
experiment were combined and binned into 1 a.u. bins for
distribution analysis. The arrows and dashed lines indicate the
cutoff levels used in panels B and D. (B) mAb 5F3. (D) mAb 50–69.
The percentage of particles stained with an intensity greater than
25 a.u. was calculated. This value represents the area under the
curve for each virus that falls above the cutoff intensity. N=3 (50–
69 and 5F3 binding to DCT and PR- DCT), 4 (50–69 and 5F3
binding to WT and PR-); error bars represent SEM.
(PDF)
Figure S11 Binding of Alexa Fluor 647-labeled Fab
fragments to HIV-1 virions. HIV-1 virions containing GFP-
Vpr were incubated with Alexa Fluor 647-labeled Fab fragments
(1 mg/mL) and analyzed for fluorescence by confocal microscopy
and Metamorph. The data were compiled from three independent
experiments where at least six independent fields were evaluated
for the median average intensity per particle. N=3; error bars
represent SEM. (A) Fab b12. (B) Fab 4E10.
(PDF)
Figure S12 Distribution analysis of particle areas.
Particles for each virus type were binned according to particle
area for one independent experiment. Two examples are shown
for mAb b12 (A) and mAb 4E10 (B). The right panels are an
overlay of the left two panels. Numbers in parentheses represent
the number of particles in each distribution.
(PDF)
Figure S13 GFP intensity, Cy5 intensity, and particle
area correlation analysis for a mAb 4E10 binding
experiment. (A) Scatter plot of average GFP-Vpr signal intensity
versus average Cy5 signal intensity showing a lack of correlation.
(B) Scatter plot of average GFP-Vpr signal intensity versus particle
area showing a lack of correlation. (C) Scatter plot of average Cy5
signal intensity versus particle area showing both a lack of
correlation and high levels of mAb 4E10 binding to PR- virions
over the full range of particle sizes.
(PDF)
Table S1 Primary antibody concentrations used in
antibody binding assays.
(PDF)
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